Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: irinotecan hydrochloride
Drug: etoposide

First Posted Date: 2003-01-27

Last Posted Date: 2018-07-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 671

Registration Number: NCT00045162

Locations: 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸
MetroHealth's Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States

and more 399 locations

Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Phase 3

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Riverside Haematology Group

Target Recruit Count: 400

Registration Number: NCT00003602

Locations: 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 1

Completed

Conditions: Ovarian Cancer
Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT00002558

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 120

Registration Number: NCT00040690

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002598

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 3

Registration Number: NCT00014313

Locations: 🇬🇧
Institute of Cancer Research - UK, Sutton, England, United Kingdom

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Children's Hospital Los Angeles

Registration Number: NCT00025324

Locations: 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 1 locations

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Target Recruit Count: 2000

Registration Number: NCT00005823

Locations: 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧
University College Hospital, London, England, United Kingdom
🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: III. Medizinische Klinik Mannheim

Target Recruit Count: 1000

Registration Number: NCT00025402

Locations: 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪
Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany

and more 175 locations

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Sarcoma
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Societe Internationale d'Oncologie Pediatrique

Registration Number: NCT00025441

Locations: 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, England, United Kingdom
🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy